Careers
Help us push the boundaries of medical imaging.
Why Work for SpinTech
- R
- 1
- 2
- 9
Real Impact
Your work with us will directly impact clinicians to quickly diagnose life-threatening neurological conditions, and it supports leading research for life-saving pharmaceuticals and treatments.
Culture of Problem Solving
People who thrive at SpinTech are passionate about overcoming challenges, unlocking potential and advancing the industry. Our team celebrates the unique talents of every player and we collaborate tightly together to solve problems.
Grow with Us
With the backing of diverse investors and exclusive industry partnerships, SpinTech is positioned for rapid growth. This is your chance to gain valuable experience at the leading edge of technology.
OPEN POSITIONS
DON’T SEE WHAT YOU’RE LOOKING FOR?
Join Our Team
UPLOAD A RESUME
News
All NewsNews
ASN 2023: The Arrival of Practical QSM Tools Enhanced for Everyday Clinical Practice
Attendees at this year’s American Society of Neuroimaging annual meeting will have their first opportunity to see and hear how quantitative MRI (qMRI) and quantitative susceptibility mapping (QSM) tools are now practical for – and being used in — everyday clinical practice. QSM is just one of the advanced outputs available with STAGE and is… “ASN 2023: The Arrival of Practical QSM Tools Enhanced for Everyday Clinical Practice”
News
Health system priorities for AI and two important questions for radiology leaders
A new report from UPMC’s Center for Connected Medicine and KLAS Research about the AI use cases that health systems are prioritizing over the next few years includes findings about plans for radiology AI that raise two important questions for neuroradiologists and healthcare leaders: Based on a survey of 58 executives and senior managers at… “Health system priorities for AI and two important questions for radiology leaders”
News
STAGE and the Promise and Challenges of New Alzheimer’s Drug Therapies
Radiologists, neurologists, Alzheimer’s patients and their families are rightfully encouraged by the range of new drugs in development to slow or reduce cognitive decline. At the start of 2023 there were 187 trials for 141 drugs addressing Alzheimer’s pathologies. Two drugs, aducanumab and lecanemab, have received accelerated FDA approval in the past two years. A… “STAGE and the Promise and Challenges of New Alzheimer’s Drug Therapies”
